Hearing Loss: Aminoglycoside-Induced Mitochondrial Deafness
Streptomycin-Induced deafness; Streptomycin Ototoxicity; MT-RNR1-Related Hearing Loss and Deafness
- MTRNR1
- MTTS1
Blood; gDNA.
For details about specimen requirements, please refer to: Specimen Type & Requirements (PDF).
5-10 mL EDTA or ACD 0.5 mL EDTA (neonate); minimum 10 ug in 100 uL low TE (pH8.0)
Room Temperature
Special Instructions for Genome Diagnostics Samples
If sample shipment >48 hours, ship on ice.
Non-syndromic mitochondrial hearing loss is characterized by moderate to profound hearing loss, and a maternally inherited mutation in either the MTRNR1 or MTTS1 gene. Individuals with an MTRNR1 mutation may have a predisposition to aminoglycoside ototoxicity causing deafness and/or late onset sensorineural hearing loss. In these individuals, hearing loss associated with aminoglycoside ototoxicity is bilateral and severe to profound, and occurs within a few days to weeks after administration of any amount of aminoglycoside antibiotic. Individuals with an MTTS1 mutation generally have an onset of sensorineural hearing loss during childhood. Variability in clinical findings may be due to the presence of variable numbers of mitochondria containing mutations in different tissues of the body (heteroplasmy).
Hearing Loss: Aminoglycoside-Induced Mitochondrial Deafness
Browse tests by laboratory
Customer Service
Toll Free: 1-855-381-3212
Local: 416-813-7200